Nascent Biotech
Burnsville, US
Nascent Biotech develops proprietary human monoclonal antibodies and immunotherapy for cancer treatment, with a lead therapeutic asset (Pritumumab) validated in brain cancer patients. The company is pursuing novel targets with a broad pipeline of therapies and diagnostics, supported by platform drug delivery technology.
Founders & leadership
LH
Lowell HoldenChief Financial Officer
SC
Sean CarrickChief Executive Officer
BP
Brandon PriceExecutive
MG
Mark GlassyExecutive
Reported raises · per SEC filings
Form D private placements$542.5K disclosed across 1 round · 2014
▶$542.5KraisedOct 2014 · 22 investors · BiotechnologyRule 506(b)
▶$542.5KraisedOct 2014 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lowell HoldenExecutive Officer, Director
- Sean CarrickExecutive Officer, Director
- Brandon PriceExecutive Officer, Director
- Mark GlassyExecutive Officer, Director
- Offering amount
- $1.4M
- Amount sold
- $542.5K
- Minimum investment
- $10K
- First sale
- Mar 2014
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Nascent Biotech do?
- Nascent Biotech develops proprietary human monoclonal antibodies and immunotherapy for cancer treatment, with a lead therapeutic asset (Pritumumab) validated in brain cancer patients. The company is pursuing novel targets with a broad pipeline of therapies and diagnostics, supported by platform drug delivery technology.
- How much funding has Nascent Biotech raised?
- Nascent Biotech has disclosed $542.5K raised across 1 round.
- Where is Nascent Biotech headquartered?
- Nascent Biotech is headquartered in Burnsville, US.